BioClinica, a Pennsylvania-based CRO, has appointed John Hubbard, Ph.D., FCP, as CEO and to its board of directors. Hubbard will assume the CEO position on Jan. 5, 2015 from Mark Weinstein.

During his 30-year career, Hubbard has spearheaded pharmaceutical R&D initiatives for multiple organizations. He joins the company from Pfizer, where he was senior vice president and worldwide head of development operations. He was responsible for more than 450 phase I-IV clinical projects per year. He also worked on the taskforce that redesigned Pfizer's R&D organization.

Previously, Hubbard was group president of Icon's clinical research services business, the company's largest business division. He also has held management positions at Parexel International, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).

Hubbard is a member of the Society of Clinical Pharmacology and Therapeutics and DIA, working on its Special Interest Advisory Committee on project management.